Lipophilic drug sequestration via intravascular lipid sink effect

The term "Lipophilic drug sequestration via intravascular lipid sink effect" does not refer to a specific molecular target such as a receptor, enzyme, transporter, or ion channel. Instead, it describes a pharmacokinetic phenomenon observed during the administration of intravenous lipid emulsions (ILE), particularly in the context of treating overdoses with highly lipophilic drugs like bupivacaine. The lipid sink theory posits that ILE creates an expanded intravascular compartment rich in triglyceride micelles. These micelles have a high affinity for binding lipophilic compounds. When administered during acute toxicity events—most notably local anesthetic systemic toxicity—the ILE acts by absorbing circulating toxic agents out of aqueous plasma and away from vital organs like the heart and brain. This reduces tissue exposure to the toxin and facilitates redistribution toward less sensitive tissues where detoxification can occur.[1][2][3] More recent research supports a dynamic "lipid shuttle" model rather than just static sequestration.[1] This mechanism is not mediated by any single protein or molecular structure but is instead based on physicochemical partitioning principles between aqueous plasma and the introduced bulk-phase triglyceride droplets.[6] Therefore, this entry should not be considered a canonical therapeutic target; it is best classified under "Other" for molecular classification. In summary, while **intravascular lipid sink effect** plays an important clinical role in managing certain poisonings/overdoses through non-specific pharmacokinetic mechanisms involving physical sequestration rather than direct molecular targeting,[5] it does not represent a discrete biological molecule suitable for structured database entries as would be appropriate for receptors or enzymes.

Other names

Lipid sink effectIntravascular lipid sinkLipid emulsion therapy (as a related intervention)Lipid rescueIntravenous lipid emulsion (ILE) sequestration

Sequestration of lipophilic drugs into an expanded intravascular lipid phase (“lipid sink”), reducing their concentration in target tissues such as the heart and brain[1][2][3][6] - Redistribution (“lipid shuttle”) of sequestered drug from sensitive organs to less critical tissues for storage or metabolism, such as muscle and liver[1][2][3]